GlaxoSmithKline and Developing Country Access to Essential Medicines (A)

The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures?
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.5840/jbee2005218
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history Request removal from index
Download options
PhilPapers Archive

Upload a copy of this paper     Check publisher's policy on self-archival     Papers currently archived: 15,914
External links
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library
References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles
Harvey E. Bale (2005). Industry, Innovation and Social Values. Science and Engineering Ethics 11 (1):31-40.

Monthly downloads

Added to index


Total downloads

18 ( #150,906 of 1,725,584 )

Recent downloads (6 months)

11 ( #59,851 of 1,725,584 )

How can I increase my downloads?

My notes
Sign in to use this feature

Start a new thread
There  are no threads in this forum
Nothing in this forum yet.